一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> International Journal of Molecular Sciences >>article
International Journal of Molecular Sciences

International Journal of Molecular Sciences

IF: 5.6
Download PDF

Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells

Published:21 July 2024 DOI: 10.3390/ijms25147959
Tianlu Zhang, Kai Yin, Xidong Niu, Xue Bai, Zhaoting Wang, Mengmeng Ji, Baoyin Yuan

Abstract

Esophageal cancer ranks the seventh in cancer incidence and the sixth in cancer death. Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of the total cases of esophageal cancer. Chemotherapy is the most effective drug-based method for treatment of esophageal cancer. However, severe side effects of traditional chemotherapy limit its treatment efficacy. Targeted chemotherapy can deliver chemotherapeutic drugs to cancer cells and specifically kill these cells with reduced side effects. In the work, the bivalent aptamer-DNA carrier (BAD) was designed by using an ESCC cell-specific aptamer as the recognition molecule and a GC base-rich DNA sequence as the drug carrier. With doxorubicin (Dox) as chemotherapeutic drugs, the bivalent aptamer-DNA-Dox conjugate (BADD) was constructed for targeted killing of ESCC cells. Firstly, the truncated A2(35) aptamer with a retained binding ability was obtained through optimization of an intact A2(80) aptamer and was used to fuse with DNA carrier sequences for constructing the BAD through simple DNA hybridization. The results of gel electrophoresis and flow cytometry analysis showed that the BAD was successfully constructed and had a stronger binding affinity than monovalent A2(35). Then, the BAD was loaded with Dox drugs to construct the BADD through noncovalent intercalation. The results of fluorescence spectra and flow cytometry assays showed that the BADD was successfully constructed and can bind to target cells strongly. Confocal imaging further displayed that the BADD can be specifically internalized into target cells and release Dox. The results of CCK-8 assays, Calcein AM/PI staining, and wound healing assays demonstrated that the BADD can specifically kill target cells, but not control cells. Our results demonstrate that the developed BADD can specifically deliver doxorubicin to target ESCC cells and selectively kill these cells, offering a potentially effective strategy for targeted chemotherapy of ESCC.

Similar articles

IF:27.4

Development of an Inhalable DNA Tetrahedron MicroRNA Sponge

Advanced Materials Lan Yao, Geru Zhang,etc Published: 22 November 2024
IF:1.6

Maslinic Acid Induces DNA Damage and Impairs DNA Repair in Human Cervical Cancer HeLa Cells.

Anticancer research Kung-Wen Lu, Mei-Due Yang,etc Published: 1 December 2020
杭锦后旗| 乐都县| 中西区| 临朐县| 绥宁县| 抚宁县| 洪洞县| 旅游| 玉林市| 兴隆县| 城固县| 陇南市| 白水县| 西华县| 芜湖县| 正安县| 武鸣县| 淮滨县| 左贡县| 定南县| 邳州市| 防城港市| 筠连县| 四平市| 新河县| 桓仁| 鹤壁市| 恩平市| 长武县| 红河县| 丰县| 广饶县| 太谷县| 册亨县| 东平县| 轮台县| 贵阳市| 新昌县| 正阳县| 浦东新区| 彝良县|